Novel therapies for schizophrenia: Understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission

Recent Patents on CNS Drug Discovery

Volumn 4, Issue 3, 2009, Pages 220-238

  Hui, Christina ^a   Wardwell, Brian ^a   Tsai, Guochuan E ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

AMPA; Ampakine; Cognitive symptoms; D serine; Glycine; Metabotropic glutamate receptors; Negative symptoms; NMDA; Sarcosine

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPHETAMINE; CLOZAPINE; CYCLOSERINE; DEXTRO ALANINE; DEXTRO AMINO ACID OXIDASE; DEXTRO SERINE; DIZOCILPINE; DYSBINDIN; GENE PRODUCT; GLYCINE; IONOTROPIC RECEPTOR; KAINIC ACID; KETAMINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROTEIN DAOA; RACEMASE; RISPERIDONE; SARCOSINE; SERINE RACEMASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ALLOSTERISM; ASTROCYTE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; EYE MOVEMENT DISORDER; GENETIC RISK; HUMAN; MEMORY DISORDER; MISMATCH NEGATIVITY; MOLECULAR INTERACTION; NAUSEA; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; POSITIVE SYNDROME; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSIS; RECEPTOR BINDING; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SEIZURE; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; SYNAPTOSOME; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; PATENTS AS TOPIC; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 70449482496     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488909789104857     Document Type: Review

References (156)

1. nd ed. New York: The Macmillan Company 1912.
2. Bleuler Eugene. Dementia praecox or the group of schizophrenias. New York: International Universities Press 1952.
3. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: Past issues and future opportunities. Neuropsychopharmacology 2008; 33(9): 2061-2079.
4. Tsai G, Coyle JT. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002; 42: 165-179.
5. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158(4): 518-526. (Pubitemid 32289814)
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209-11023
7. Lodge D, Johnson KM. Noncompetitive excitatory amino acid antagonists. Trends Pharmacol Sci 1990; 11(2): 81-86. (Pubitemid 20041667)
8. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999; 33(6): 523-533.
9. Bliss TVP, Collingridge GL. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993; 361(6407): 31-39. (Pubitemid 23020772)
10. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: Excitatory times ahead. Lancet Neurol 2008; 7(8): 742-755.
11. Perez-Otano I, Ehlers MD. Learning from NMDA receptor trafficking: Clues to the development and maturation of glutamatergic synapses. Neurosignals 2004; 13(4): 175-189. (Pubitemid 38698090)
12. Balazs R, Bridges RJ, Cotman CW. Excitatory amino acid transmission in health and disease. New York: Oxford University Press 2006.
13. Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 2008; 30(1): 25-31.
14. Lau CG, Zukin RS. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 2007; 8(6): 413-426. (Pubitemid 46789232)
15. Kemp JA, Leeson PD. The glycine site of the NMDA receptor-five years on. Trends Pharmacol Sci 1993; 14(1): 20-25. (Pubitemid 23034603)
16. Coyle JT. Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26(4-6): 365-384.
17. Takamori S, Rhee JS, Rosenmund C, Jahn R. Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature 2000; 407(6801): 189-194.
18. Bergeron R, Coyle JT, Tsai G, Geene RW. NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 2005; 30(1): 7-16. (Pubitemid 40024394)
19. Corlew R, Wang Y, Ghermazien H, Erisir A, Philpot BD. Developmental switch in the contribution of presynaptic and postsynaptic NMDA receptors to long-term depression. J Neurosci 2007; 27(37): 9835-9845. (Pubitemid 47403998)
20. Guo X, Hamilton PJ, Reish NJ, Sweatt JD, Miller CA, Rumbaugh G. Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of schizophrenia. Neuropsychopharmacol 2009; 34(7): 1659-1672.
21. Márquez J, Tosina M, Rosa V, et al. Campos-Sandoval New insights into brain glutaminases: Beyond their role on glutamatergic transmission. Neurochem Int 2009; 55(1-3): 64-70.
22. Schluter K, Fiegiel M, Rozyczka J, Engele J. CNS region-specific regulation of glial glutamate transporter expression. Eur J Neurosci 2002; 16(5): 836-842. (Pubitemid 35463575)
23. Coyle JT, Tsai G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 2004; 59: 491-515. (Pubitemid 39752426)
24. Miya K, Inoue R, Takata Y, et al. Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 2008; 510(6): 641-654.
25. Itil T, Keskiner A, Kiremitici N, Holden JMC. Effect of phenylcyclidine in chronic schizophrenics. Can Psychiatr Assoc J 1967; 12(2): 209-212.
26. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psych 1959; 81(3): 363-369.
27. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148(10): 1301-1308.
28. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of noncompetitive NMDA antagonist, ketamine, in humans. Psychomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51(3): 199-214.
29. Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induces NMDA receptor hypofunction as a model of memory impairments and psychosis. Neuropsychopharmcology 1999; 20(2): 106-118. (Pubitemid 29010370)
30. Malhotra AK, Pinals DA, Adler CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairments in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17(3): 141-150.
31. Lahti AC, Weiler MA, Michaelidis T, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25(4): 455-467. (Pubitemid 32830950)
32. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmcol 2001; 156(2-3): 234-258.
33. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmcol 2008; 199(3): 331-388.
34. Swerdlow NR, Bakshi V, Waikar M, Taaid N, Geyer MA. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmcology 1998; 140(1): 75-80. (Pubitemid 28524310)
35. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers; implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000; 57(12): 1139-1147.
36. Weiler MA, Thaker GK, Lahti AC, Tamminga CA. Ketamine effects on eye movements. Neuropsychopharmacology 2000; 23(6): 645-653.
37. Avila MT, Weiler MA, Lahti AC, Tamminga CA, Thaker GK. Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am J Psychiatry 2002; 159(9): 1490-1496.
38. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Picker D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154(6): 805-811. (Pubitemid 27230103)
39. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry 2000; 48(7): 627-640. (Pubitemid 30734231)
40. Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology 2000; 22(4): 400-412.
41. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 2005; 30(12): 2275-2282. (Pubitemid 41643980)
42. Jentsch JD, Tran A, Taylor JR. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: Behavior and neurochemical evidence. Psychopharmacology 1998; 138(1): 89-95. (Pubitemid 28319052)
43. Schiffer WK, Logan J, Dewey SL. Positron emission tomography studies of potential mechanisms underlying phencyclidine-induced alterations in striatal dopamine. Neuropsychopharmacology 2003; 28 (12): 2192-2198. (Pubitemid 37468187)
44. Farber NB, Newcome JW, Olney JW. Glycine agonists what can they teach us about schizophrenia? Arch Gen Psychiatry 1999; 56(1): 13-17.
45. Tsukada H, Nishiyama S, Fukumoto D, Sato, K, Kakiuchi T, Domino EF. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 2005; 30(10): 1861-1869. (Pubitemid 41486411)
46. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 2005; 10(1): 40-68. (Pubitemid 40139588)
47. Boks MPM, Rietkerk T, van de Beek MH, Sommer IE, de Koning TJ, Kahn RS. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia. Eur Neuropsychopharmcol 2007; 17(9): 567-572. (Pubitemid 47078999)
48. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci 2002; 99(21): 13675-13680. (Pubitemid 35215440)
49. Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of d-Serine in patients with schizophrenia; Evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60(6): 572-576. (Pubitemid 36682314)
50. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M. Reduced d-Serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharm Bio Psychiatry 2005; 29(5): 767-769. (Pubitemid 40897791)
51. Stevens ER, Esguerra M, Kim PM, et al. D-Serine and serine racemase are present in the vertebrate retina and contribute to the physiological activation of NMDA receptors. Proc Natl Acad Sci USA 2003; 100(10): 6789-6794. (Pubitemid 36666658)
52. Tsai G, Yang P, Chung L, Lange N, Coyle JT. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44(11): 1081-1089 (Pubitemid 28547143)
53. Herseco-Levy U, Javitt DC, Ebstein R, et al. D-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57(6): 577-585. (Pubitemid 40409697)
54. Corvin A, Donohoe G, McGhee K, et al. D-Amino acid oxidase (DAO) genotype and mood symptomatology in schizophrenia. Neurosci Lett 2007; 426(2): 97-100. (Pubitemid 47464716)
55. Bendikov I, Nadri C, Amar S, et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophrenia Res 2007; 90(1-3): 41-51. (Pubitemid 46177566)
56. Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H, Panizzutti R. Increased brain D-amino acid-oxidase (DAAO) activity in xchizophrenia. Schizophrenia Res 2008; 101(1-3): 76-83.
57. Hashimoto K, Fujita Y, Horio M, et al. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry 2009; 65(12): 1103-1106.
58. Morita Y, Ujike H, Tanaka Y, et al. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol Psychiatry 2007; 61(10): 1200-1203. (Pubitemid 46669458)
59. Fujii K, Maeda K, Hikida T, et al. Serine racemase binds to PICK1: Potential relevance to schizophrenia. Mol Psychiatry 2006; 11(2): 150-157. (Pubitemid 43164616)
60. Hikida T, Mustafa AK, Maeda K, et al. Modulation of D-serine levels in brains of mice lacking PICK1. Biol Psychiatry 2008; 63(10): 997-1000.
61. Basu AC, Tsai GE, Ma CL, et al. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry 2009; 14(7): 719-727.
62. Wroblewska B, Wroblewski JT, Pshenichkin S, Surin A, Sullivan SE, Neale JH. N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J Neurochem 1997; 69(1): 174-181. (Pubitemid 27274170)
63. Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008; 31(5): 234-242.
64. Marti SB, Cichon S, Propping P, Nothen M. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Gen 2002; 114(1): 46-50.
65. Fujii Y, Shibata H, Kikuta R, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatry Genet 2003; 13(2): 71-76. (Pubitemid 36724534)
66. Egan MF, Straub RE, Goldberg TE, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 2004; 101(34): 12604-12609.
67. Marenco S, Steele SU, Egan MF, et al. Effect of metabotropic glutamate receptor 3 genotype on n-acetylaspartate measures in the dorsolateral prefrontal cortex. Am J Psychiatry 2006; 163(4): 740-742. (Pubitemid 44464589)
68. Straub RE, Jiang Y, MacLean CJ, et al. Genetic variation in the 6P22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genetics 2002; 71(2): 337-348. (Pubitemid 34800250)
69. Schwab SG, Knapp M, Mondadon S, et al. Support for association of schizophrenia with genetic variation in the 6P22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003; 72(1): 185-190. (Pubitemid 36056855)
70. Talbot K, Eidem WL, Tinsley CL et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest 2004; 113(9): 1353-1363. (Pubitemid 39069934)
71. Burdick KE, Goldber TE, Funke B, et al. DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophrenic Res 2007; 89(1-3): 169-172. (Pubitemid 44881303)
72. DeRosse P, Funke B, Burdick KE, et al. Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry 2006; 163(3): 532-534. (Pubitemid 44469399)
73. Stefansson H, Siqurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71(4): 877-892.
74. Stefansson H, Sarginson J, Kong A, et al. Association of neuregulin 1 with schizophrenia confirmed in a scottish population. Am J Hum Genet 2003; 72(1): 83-87. (Pubitemid 36056844)
75. Williams NM, Preece A, Spurlock G, et al. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry 2003; 8(5): 485-487. (Pubitemid 36829690)
76. Yang JZ, Si TM, Ruan Y, et al. Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry 2003; 8(7): 706-709. (Pubitemid 36976302)
77. Petryshen TL, Middleton FA, Kirby A, et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry 2005; 10(4): 366-374. (Pubitemid 40490804)
78. Georgieva L, Dimitrova A, Ivanov D, et al. Support for neuregulin 1 as a susceptibility gene for bipolar disorder and schizophrenia. Biol Psychiatry 2008; 64(5): 419-427.
79. Li B, Woo RS, Mei L, Malinow R. ErbB4, a receptor of the schizophrenia-linked protein neuregulin-1, controls glutamatergic synapse maturation and plasticity. Neuron 2007; 54(4): 583-597.
80. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006; 12(7): 824-828
81. Gundez-Bruce H. The acute effects of NMDA antagonism: From the rodent to the human brain. Brain Res Rev 2009; 60(2): 279-286.
82. Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets-CNS Neurol Disord 2002; 1(2): 183-189.
83. Tsai GE. New approaches to treatment of schizophrenia by enhancing N-methyl-D-aspartate neurotransmission. Prog Neurother Neuropsychopharm 2008; 3(1): 275-289.
84. Labrie V, Lipina T, Roder JC. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 2008; 200(2): 217-230.
85. Javitt, D.C., Zukin, S.R.: US5854286 (1998).
86. Javitt, D.C.: US5837730 (1998).
87. Tsai, G., Coyle, J.: US20056974821 (2005).
88. Tsai, G., Coyle, J.: US20026420351 (2002).
89. Tsai, G., Coyle, J.: US20036667297 (2003).
90. Tsai, G., Coyle, J.: US20016228875 (2001).
91. Javitt, D.C.: US20006162827 (2000).
92. Javitt, D.C.: US20026355681 (2002).
93. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis. Schizophrenia Res 2005; 72: 225-234. (Pubitemid 39550993)
94. Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2006; Issue 2.\ Art. No: CD003730. DOI: 10.1002/14651858.CD003730.pub2.
95. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta analysis. Curr Pharm Des 2009 [in press].
96. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999; 56(1): 29-36. (Pubitemid 29055047)
97. Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in treatment of schizophrenia: Focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008; 258(1): 16-27.
98. Rosse RB, Theut SK, Banay-Schwartz M, et al. Glycine adjuvant therapy to conventional neurlopetic treatment in schizophrenia: An open-label pilot study. Clin Neuropharm 1989; 12(5): 416-424 (Pubitemid 20008765)
99. Javitt DC, Silipo G, Cienfuegoa A, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharm 2001; 4(4): 385-391. (Pubitemid 33151682)
100. Herseco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004; 55(2): 165-171. (Pubitemid 38367720)
101. Goff D, Tsai G, Manoach D, Coyle J. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in Schizophrenia. Am J Psychiatry 1995; 152(8): 1213-1215.
102. Vítek V, Rysánek K, Horáková Z, Muratová J, Vojtěchovský M, Vejdovský R. Differential behavioural and biochemical effects on the central nervous system by cycloserine isomers. Psychopharmacologia 1965; 7(3): 203-219.
103. Van Berckel BNM, Hijman R, van der Linen JA, Westenberg H, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996; 40(12): 1298-11230 (Pubitemid 27006415)
104. Goff DC, Herz L, Poseover T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacol 2005; 179(1): 144-150. (Pubitemid 40576701)
105. Evins AE, Amico E, Posever T, Toker R, Goff D. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Res 2002; 56(1-2): 19-23. (Pubitemid 34655463)
106. Heresco-Levy U, Javitt D, Ermilov M, Silipo G, Shimoni J. Double-blind, placebo-controlled, crossover trial of d-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharm 1998; 1(2): 131-135. (Pubitemid 128538374)
107. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 199; 56(1): 21-27.
108. Goff DC, Cather C, Gottlieb JD, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study. Schizophrenia Res 2008; 106(2-3): 320-327.
109. Tsai G, Yang P, Chung L, Lange N, Coyle, J. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 1998; 44(11): 1081-1089. (Pubitemid 28547143)
110. Herseco-Levy U, Javitt DC, Ebstein R, et al D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 2005; 57(6): 577-585. (Pubitemid 40409697)
111. Tsai GE, Yang P, Chang Y, Chong, M. D-Alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2006; 59(3): 230-234. (Pubitemid 43208969)
112. Tsai G, Ralph-Williams RJ, Martina M, et al. Gene Knockout of Glycine Transporter-1: Characterization of the Behavioral Phenotype. Proc Natl Acad Sci USA 2004; 101(22): 8485-8490. (Pubitemid 38736601)
113. Tsai G, Lane H, Yang P, Chong M, Lange N. Glycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55(5): 452-456.
114. Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study. Biol Psychiatry 2008; 63(1): 9-12. (Pubitemid 350234891)
115. Diaz P, Bhaskara S, Dursun SM, Deakin B. Double-blind placebo controlled, crossover trial of clozapine puls blycine in refractory schizophrenia negative results. J Clin Psychopharmacol 2005; 25(3): 277-278. (Pubitemid 40685796)
116. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cyloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153(12): 1628-1630. (Pubitemid 26406177)
117. Tsai GE, Yang P, Chung L, Tsai I, Tsai C, Coyle JT. D-Serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 1999; 156(11): 1822-1825. (Pubitemid 29517581)
118. Lane HY, Huang CL, Wu PL, et al. Glycine transporter 1 inhibitor, N-methylglycine (sarcosine) added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60(6): 645-649.
119. Ninan I, Jardemark KE, Liang X, Wang RY. Calcium/calmodulin-dependent kinase II is involved in the facilitating effect of clozapine on NMDA- and electrically evoked responses in the medial prefrontal cortical pyramidal cells. Synapse 2003; 47(4): 285-294. (Pubitemid 36160121)
120. Melone M, Vitellaro-Zuccarello L, Vallejo-iIllarramendi A, et al. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 2001; 6(4): 380-386. (Pubitemid 32566086)
121. Lopez-Gil X, Babot Z, Amargos-Bosch M, Sunol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacol 2007; 32(10): 2087-2097. (Pubitemid 47417703)
122. Buchanan RW, Javitt DC, Marder SR, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164(10): 1593-1602.
123. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai G. Sarcosine ordD-serine add-on treatment for acute exacerbation of schizophrenia. Arch Gen Psychiatry 2005; 62(11): 1196-1204.
124. Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placeb-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009; 34(5): 1322-1329.
125. Smith SM, Uslaner JM, Lihang Y, et al. The behavioral and neurochemical effects of a novel d-amino acid oxidase inhibitor compound 8 [4H-Thieno[3,2-b]oyrrole-5-carboxylic acid] and D-serine. J Pharm Exp Ther 2009; 328(3): 921-930.
126. Adage T, Trillat A, Quattropani A, et al. in vitro and in vivo Pharmacological profile of AS057278, a selective D-amino acid oxidase inhibitor with potential antipsychotic properties. Eur Neuropsychopharmcol 2008; 18(3): 200-214.
127. Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007; 12(10): 904-922. (Pubitemid 47482704)
128. Conn PJ, Jones CK. Promise of mGluR2/3 activators in psychiatry. Neuropsychopharmacol Rev 2009; 34(1): 248-249.
129. Herron CE, Lester RA, Coan EJ, Collingridge GL. Frequency-dependent involvement of NMDA receptors in the hippocampus: A novel synaptic mechanism. Nature 1986; 322(6076): 265-268.
130. Issac JT, Nicoll RA, Malenka RC. Silent glutamatergic synapses in the mammalian brain. Can J Physiol Pharmacol 1999; 77(9): 735-737.
131. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21(5): 484-487. (Pubitemid 32937430)
132. Bassani S, Valngegri P, Beretta F, Passafaro M. The GluR2 subunit of AMPA receptors: Synaptic role. Neuroscience 2009; 158(1): 55-61.
133. Swanson GT. Targeting AMPA and kainite receptors in neurological disease: Therapies on the horizon? Neuropsychopharmcol Rev 2009; 34(1): 249-250.
134. Johnson, S.A., Lynch, G.S., Rogers, G.A.: US20006166008 (2000).
135. Black MD, Wotanis J, Schilp DE, Hanak SE, Sorensen SM, Wettstein JG. Effect of AMPA receptor modulators on hippocampal and cortical function. Eur Pharmacol 2000; 394(1): 85-90. (Pubitemid 30193292)
136. Nagarajan N, Quast C, Boxall AR, Shahid M, Rosenmund C. Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. Neuropharmacol 2001; 41(6): 650-663. (Pubitemid 32972182)
137. Marenco S, Egan MF, Goldberg TE, Knable MB, McClure RK, Winterer G. Preliminary experience with an ampakine (CX516) as a single agent for treatment of schizophrenia: A case series. Schizophrenia Res 2002; 57(2-3): 221-226. (Pubitemid 35240024)
138. Goff DC, Lamberti JS, Leon AC, et al. A placebo add-on trial of the Ampakine, CX516, for cognitive deficients in schizophrenia. Neuropsychopharmacology 2008; 33(3): 465-472.
139. Gasparini F, Spooren W. Allosteric modulators for mGlu receptors. Curr Neuropharm 2007; 5(3): 187-194.
140. Cambia. Patent Lens [Online]. [Cited 2009 Apr 14]. Available from: http: //www.patentelents.net/patentlens/simple.cgi#list.
141. Chenard, B.L.: US20006136861 (2000).
142. Chenard, B.L.: US20006124361 (2000).
143. Monn, J.A., Schoepp, D.O.: US5750566 (1998).
144. Monn, J.A.: US55925782 (1999).
145. Helton, D.R., Monn, JA., Schoepp, D.O., Tizzano, J.P.: US20005925680 (2000).
146. Nakazoto, A., Kumagai, T., Kanuma, K., Sakagami, K.: US20046770676 (2004).
147. Nakazoto, A., Kumagai, T., Sakagami, K., Tomisawa, K.: US20016316498 (2001).
148. Duggan, M.E., Lindsley, C.W., Wisnoski, D.: US20097507826 (2009).
149. Algarsamy S, Marino MJ, Rouse ST, Gereau RW IV, Henemann SF, Conn PJ. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 1999; 2(3): 234-240.
150. Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, et al. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl] -piperidin-1-yl}-methanone]: A novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharm Exp Ther 2008; 327(3): 827-839.
151. Olszewski TR, Wegorzewska MM, Monteiro AC, et al. Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol Psychiatry 2008; 68(1): 86-91.
152. van Berckel BNM, Kegeles LS, Waterhouse R, et al. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonists LY354740 in non-human primates studied with positron emission topography. Neuropsychopharmacology 2006; 31(5): 967-977.
153. Patil SJ, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med 2007; 13(9): 1102-1107. (Pubitemid 47517511)
154. Russel J. Lilly schizophrenia drug fails clinical trial. Earlier tests showed promise, including none of the common side effects, but latest trial fell short. Indystar.com 2009 Mar 30. Available from: http://www.indystar.com/ article/20090330/BUSINESS03/903300304
155. US National Institutes of Health. Clinical Trials.Gov [Online] [Cited 14 Apr, 2009]. Available from: http: //www.clinicaltrials.gov
156. Woods SW, Walsh BC, Pearlson GD, McGlashan. Glycine treatment of prodromal symptoms (abstract). Schizophr Res 2006; 86(Suppl 1): S7.